Search Results - "Guiu, S."

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement by Guiu, S., Michiels, S., André, F., Cortes, J., Denkert, C., Di Leo, A., Hennessy, B.T., Sorlie, T., Sotiriou, C., Turner, N., Van de Vijver, M., Viale, G., Loi, S., Reis-Filho, J.S.

“…The 2012 IMPAKT task force investigated the medical usefulness of current methods for the classification of breast cancer into the ‘intrinsic’ molecular…”
Get full text

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer by Dent, Rebecca, Oliveira, Mafalda, Isakoff, Steven J., Im, Seock-Ah, Espié, Marc, Blau, Sibel, Tan, Antoinette R., Saura, Cristina, Wongchenko, Matthew J., Xu, Na, Bradley, Denise, Reilly, Sarah-Jayne, Mani, Aruna, Kim, Sung-Bae

“…Purpose In LOTUS (NCT02162719), adding the oral AKT inhibitor ipatasertib to first-line paclitaxel for locally advanced/metastatic triple-negative breast…”
Get full text

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study by Ploquin, A., Pistilli, B., Tresch, E., Frenel, J.S., Lerebours, F., Lesur, A., Loustalot, C., Bachelot, T., Provansal, M., Ferrero, J.M., Coussy, F., Debled, M., Kerbrat, P., Vinceneux, A., Allouache, D., Morvan, F., Dalenc, F., Guiu, S., Rouzier, R., Vanlemmens, L.

“…Breast cancer diagnosed during pregnancy (BCP) is rare, but the prevalence is expected to rise. Long-term follow-up data regarding this clinically challenging…”
Get full text

Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer by Guiu, Boris, Petit, Jean Michel, Bonnetain, Franck, Ladoire, Sylvain, Guiu, Séverine, Cercueil, Jean-Pierre, Krausé, Denis, Hillon, Patrick, Borg, Christophe, Chauffert, Bruno, Ghiringhelli, François

“…Adipose tissue releases angiogenic factors that may promote tumour growth. To determine whether body mass index (BMI), subcutaneous fat area (SFA) and visceral…”
Get more information

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact by Nabholtz, J.M., Abrial, C., Mouret-Reynier, M.A., Dauplat, M.M., Weber, B., Gligorov, J., Forest, A.M., Tredan, O., Vanlemmens, L., Petit, T., Guiu, S., Van Praagh, I., Jouannaud, C., Dubray-Longeras, P., Tubiana-Mathieu, N., Benmammar, K.E., Kullab, S., Bahadoor, M.R.K., Radosevic-Robin, N., Kwiatkowski, F., Desrichard, A., Cayre, A., Uhrhammer, N., Chalabi, N., Chollet, P., Penault-Llorca, F.

“…Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors for some of which the epithelial growth factor receptor (EGFR) pathway may play an…”
Get full text

Corrigendum to “De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis” [Eur J Cancer 158 (2021) 181–188] by Gaillard, T., Carton, M., Mailliez, A., Desmoulins, I., Mouret-Reynier, M.A., Petit, T., Leheurteur, M., Dieras, V., Ferrero, J.M., Uwer, L., Guiu, S., Gonc¸alves, A., Levy, C., Debled, M., Dalenc, F., Patsouris, A., Bachelot, T., Eymard, J.C., Chevrot, M., Conversano, A., Robain, M., Hequet, D.

Get full text

De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis by Gaillard, T., Carton, M., Mailliez, A., Desmoulins, I., Mouret-Reynier, M.A., Petit, T., Leheurteur, M., Dieras, V., Ferrero, J.M., Uwer, L., Guiu, S., Gonçalves, A., Levy, C., Debled, M., Dalenc, F., Patsouris, A., Bachelot, T., Eymard, J.C., Chevrot, M., Conversano, A., Robain, M., Hequet, D.

“…The estimated rate of de novo metastatic breast cancer (dnMBC) at the time of diagnosis is between 5 to 12%. International guidelines recommend metastatic…”
Get full text

Quantification of the visceral and subcutaneous fat by computed tomography: Interobserver correlation of a single slice technique by Sottier, D, Petit, J.-M, Guiu, S, Hamza, S, Benhamiche, H, Hillon, P, Cercueil, J.-P, Krausé, D, Guiu, B

“…Abstract Purpose To assess the interobserver reproducibility of the quantification of the visceral and subcutaneous fat by computed tomography from an…”
Get full text

Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis by Jankowski, Clémentine, Guiu, S., Cortet, M., Charon-Barra, C., Desmoulins, I., Lorgis, V., Arnould, L., Fumoleau, P., Coudert, B., Rouzier, R., Coutant, C., Reyal, F.

“…Purpose The aim of this study was to assess the Institut Gustave Roussy/M.D. Anderson Cancer Center (IGR/MDACC) nomogram in predicting pathologic complete…”
Get full text

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207) by Huober, J., Weder, P., Veyret, C., Thürlimann, B., Xyrafas, A., Vanlemmens, L., Guiu, S., Brain, E., Grenier, J., Dalenc, F., Levy, C., Savoye, A.M., Müller, A., Membrez-Antonioli, V., Gerard, M.A., Lemonnier, J., Hawle, H., Boven, E., Bonnefoi, H.

Get full text

Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status by Bertaut, A., Mounier, M., Desmoulins, I., Guiu, S., Beltjens, F., Darut-Jouve, A., Ponnelle, T., Arnould, L., Arveux, P.

“…We aim to describe trends in net survival (NS) and to assess the prognostic factors among women with de novo metastatic breast cancer (MBC) according to human…”
Get full text

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME) by Dano, D., Lardy-Cleaud, A., Monneur, A., Quenel-Tueux, N., Levy, C., Mouret-Reynier, M.-A., Coudert, B., Mailliez, A., Ferrero, J.-M., Guiu, S., Campone, M., de La Motte Rouge, T., Petit, T., Pistilli, B., Dalenc, F., Simon, G., Lerebours, F., Chabaud, S., Bertucci, F., Gonçalves, A.

“…Primary inflammatory breast cancer (IBC) is a rare and aggressive entity whose prognosis has been improved by multimodal therapy. However, 5-year overall…”
Get full text

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer by Guiu, S, Gauthier, M, Coudert, B, Bonnetain, F, Favier, L, Ladoire, S, Tixier, H, Guiu, B, Penault-Llorca, F, Ettore, F, Fumoleau, P, Arnould, L

“…Background: We analysed whether the level of human epidermal growth factor receptor-2 (HER-2) amplification significantly influenced either pathological…”
Get full text

Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy by Guiu, S., Mouret Reynier, M. A., Toure, M., Coudert, B.

“…Since 2005, major progresses have been made in the neoadjuvant treatment of HER2-positive breast cancer. Trastuzumab introduction associated with chemotherapy…”
Get full text

Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy by Guiu, S., Liegard, M., Favier, L., van Praagh, I., Largillier, R., Weber, B., Coeffic, D., Moreau, L., Priou, F., Campone, M., Gligorov, J., Vanlemmens, L., Trillet-Lenoir, V., Arnould, L., Coudert, B.

“…Very effective trastuzumab-based primary systemic therapy (PST) can be proposed for conservative surgery purpose to human epidermal growth factor receptor 2…”
Get full text

Management of metastatic HER2-positive breast cancer: present and future by Guiu, S, Coudert, B, Favier, L, Arnould, L, Fumoleau, P

“…HER2-positive breast cancer accounts for 20 to 25% of breast cancers. The surexpression of this tyrosine-kinase receptor is often associated with a poor…”
Get more information

Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study by Guiu, S, Taillibert, S, Chinot, O, Taillandier, L, Honnorat, J, Dietrich, P Y, Maire, J-P, Guillamo, J S, Guiu, B, Catry-Thomas, I, Capelle, F, Thiebaut, A, Cartalat-Carel, S, Deville, C, Fumoleau, P, Desjardins, A, Xuan, K Hoang, Chauffert, B

“…Second-line chemotherapy is disappointing in recurrent high-grade gliomas. Dramatic responses in recurrent high-grade gliomas have been reported in a recent…”
Get full text

Abstract No. 325: Addition of Pirarubicin and Amiodarone in TACE of Unresectable Hepatocellular Carcinoma: A Pilot Study by Guiu, B, Loffroy, R, Guiu, S, Boulin, M, Ghiringhelli, F, Bonnetain, F, Hillon, P, Bedenne, L, Cercueil, J, Chauffert, B, Krausé, D

Get full text

Carcinomatous Meningitis from Unknown Primary Carcinoma by Favier, L., Ladoire, L., Guiu, B., Arnould, L., Guiu, S., Boichot, C., Isambert, N., Besancenot, J.F., Muller, M., Ghiringhelli, F.

“…Carcinomatous meningitis (CM) occurs in 3 to 8% of cancer patients. Patients present with a focal symptom, and multifocal signs are often found following…”
Get full text

104P Clinical characteristics of patients (pts) with complete response (CR) to abemaciclib-based endocrine therapy (ET) in MONARCH 2 (M2) and MONARCH 3 (M3) by Huober, J., Grischke, E-M., Guiu, S., Quenel Tueux, N., Chouaki, N., Stoffregen, C., Korfel, A., Lerebours, F.

Get full text